Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Eazysense has developed the BRODERICK PROBE®, a patented and trademarked carbon-based nanobiosensor platform capable of real-time, in vivo sensing of neurotransmitters and other neurochemicals directly from the brain. The technology is being applied to neurological and psychiatric disorders for both diagnostic and therapeutic monitoring purposes. Early results demonstrate successful detection of neurotransmitter activity in animal models and human studies related to epilepsy, Parkinson’s disease with Lewy body dementia, Alzheimer’s disease, anxiety, depression, schizophrenia, among others.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Eazysense Nanotechnology.